Enhanced oral bioavailability and hepatoprotective activity of thymoquinone in the form of phospholipidic nano-constructs by Rathore, C. et al.
1 
Enhanced oral bioavailability and hepatoprotective activity of thymoquinone 
in the form of phospholipidic nano-constructs 
ABSTRACT 
Background: The poor biopharmaceutical properties of thymoquinone (TQ) obstruct its 
development as a hepatoprotective agent. To surmount the delivery challenges of TQ, 
phospholipid nanoconstructs (PNCs) were constructed. 
Method: PNCs were constructed employing microemulsification technique and systematic 
optimization by three-factor three level Box-Behnken design. 
Result: Optimized PNC composition exhibited nano size (<100 nm), spherical morphology, 
within acceptable range of polydispersity index (0.55), high drug entrapment efficiency (>90%), 
controlled drug release pattern, and neutral surface charge (zeta potential of -0.65 mV). After oral 
administration of a single dose of PNC, it showed a relative bioavailability of 386.03% vis-à-vis
plain TQ suspension. Further, TQ-loaded PNC demonstrated significant enhanced hepato-
protective effect vis-à-vis pure TQ suspension and silymarin, as evidenced by reduction in the 
ALP, ALT, AST, bilirubin and albumin level and ratified by histopathological analysis.  
Conclusion: TQ-loaded PNCs can be efficient nano-platforms for the management of hepatic 
disorders and promising drug delivery systems to enhance oral bioavailability of this hydrophobic 
molecule





Liver diseases, especially viral hepatitis occurs predominately in developing countries with an 
enormous impact on public health and economy [1,2]. Liver diseases account for approximately 2 
million deaths per year worldwide [3]. Thymoquinone (TQ: 2-isopropyl-5-methylbenzo-1,4-
quinone), the main active molecule of Nigella sativa (NS) essential oil, is a promising contender 
for the prevention of hepatic diseases [4-6]. The hepatoprotective effects of TQ may be linked with 
its ameliorating effects on inflammation, apoptosis, and oxidative stress pathways. This 
subsequently results in the less transactivation of hepatic stellate cells (HSCs) [2,7,8]. Oral 
administration of TQ alleviates oxidative stress in liver mucosa directly via its free radical 
scavenging action and/or indirectly via stimulation of endogenous enzymatic and non-enzymatic 
antioxidants enzymes [9]. Further, TQ alleviates liver inflammation by inhibiting cyclooxygenase 
pathway and eicosanoid generation in leukocytes, and also 5-lipooxygenase and peroxidase [10]. 
Although, TQ is a potential candidate for treating hepatic diseases but its highly hydrophobic 
nature limits its oral bioavailability. The solubility of TQ in aqueous medium has been reported to 
be less than < 1.0 mg/mL at room temperature. Further, it is also reported to have degradation in 
the aqueous media and in the presence of light. These limitations can be overcome by strategically 
formulating nanosized formulation of TQ such as phospholipid nanoconstructs, which can protect 
the encapsulated drug, enhance the bioavailability, passively-target the drug to the liver, and 
release the drug in a controlled and effective manner.  
Phospholipid based nanocarrier systems could be a potential delivery system for enhancing 
solubility and therapeutic efficacy (11). Presently, researchers are being focused to the 
development of newer delivery approaches to get enhanced benefit using TQ. 
Kalam et al., 2017 evaluated the hepato-protective potential of TQ-loaded self-nanoemulsifying 
drug delivery systems (SNEDDS) using CCl4 induced hepato-toxicity model. Results indicated the
significant hepatoprotective effects for optimized TQ-loaded SNEDDS vis-à-vis TQ suspension. 
The comparative bioavailability of TQ was enhanced 3.87-fold by optimized SNEDDS in 
comparison with TQ suspension. (Singh et al., 2013) evaluated the hepato-protective potential of 
TQ-loaded solid lipid nanoparticles (SLNs) against Paracetamol-induced hepatotoxicity. Findings 
revealed that TQ-SLNs significantly reduced the serum biomarker enzymes (SGOT, SGPT and 
ALP) compared to pure TQ suspension. Further, in vivo studies revealed a nearly 5-fold increase 
in the bioavailability of TQ-SLN as compared to pure TQ suspension. 
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Among various lipidic nanocarrier systems, nanostructured lipid carriers (NLCs) composed of 
lipids, blend of surfactant/co-surfactant and water seen to be effective in accomplishing the 
therapeutic requirements of TQ. Sayeed et al., prepared TQ-loaded proniosome based formulation 
for hepato-protective activity against methotrexate-induced hepato-toxicity. Findings revealed that 
TQ-loaded proniosomes significantly inhibited the elevated levels of liver enzymes, serum marker 
enzymes and improved histopathological abnormalities [12]. 
NLCs, the second-generation of lipid carriers, are composed of a mixture of spatially different 
lipids, i.e., the blend of solid lipid and liquid lipid [13,14]. NLCs stimulate oral absorption of 
encapsulated drugs via selective uptake through the lymphatic route or the payer’s patches [15-
17]. NLC formulations of TQ prepared by high shear homogenization and ultrasonication have 
earlier been reported to improve the therapeutic efficacy of the drug in animal models for the 
treatment of gastric ulcer [18] tumor [19] and hepatic disorders [9]. In comparison to the previously 
employed methods to prepare TQ-loaded NLCs, microemulsification method is simple, 
reproducible, no energy requirement, cost-effective and can be easily scaled-up. Moreover, NLCs 
with low particle size, narrow size distribution and high entrapment efficiency can be obtained. 
The combination of surfactants usually produces smaller particle sizes due to the surface-active 
property of the surfactants. Thus, in the present research work, we have attempted to incorporate 
phospholipid (i.e., Phospholipon 90G) as surfactant-co-surfactant mixture (Smix) with a non-ionic 
surfactant (i.e., Tween 80) so as to result in the construction of the phospholipid nanoconstructs 
(PNCs) employing microemulsification method. No report is traceable in the literature regarding 
the phospholipid based NLCs for TQ. Phospholipon 90G is a Zwitterionic surfactant and is 
expected to enhance the biopharmaceutical performance and therapeutic efficacy of hydrophobic 
drug molecules. It tends to provide enhanced solubility and permeability of the drugs across the 
biological barriers, thus improving their oral biopharmaceutical performance owing to its 
amphiphilic nature. Additionally, phospholipids constitute a major part of the bio-membrane and 
thus enhance the cellular uptake of the drugs [20]. Besides this, being amphiphilic compound 
phospholipids when placed in water from micelles like structure or are organized as lipid bilayers 
with the hydrophobic tails facing against one another and the hydrophilic head-group facing the 
water on both sides. These unique features make phospholipids most appropriate to be used as co-
surfactant for poorly water-soluble drugs like TQ. Thus, kept in mind that the enhanced oral 
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absorption of hydrophobic drugs via intrinsic lipid pathways can be achieved by incorporating the 
drug into phospholipid based systems. 
The best understanding of the product and process during the development of a formulation could 
be achieved employing design of experiments (DoE), which is an excellent tool to systematically 
manipulate factors according to a prespecified design [21]. Box-Behnken design (BBD), is one 
such DoE response surface methodology design, having numerous design advantages in 
comparison to other second order designs, e.g., central composite design (CCD) [22-24]. Thus, in 
the present investigation, BBD was used to optimize the TQ-loaded PNCs. Solid lipid, liquid lipid 
and surfactant/co-surfactant blend i.e., (Smix): (T80:PL90G), were employed as the input variables 
for studying their effect on the responses like particle size and entrapment efficiency. The best-
optimized TQ-loaded PNC was then evaluated for in vitro release kinetics to study the release 
mechanism, pharmacokinetic assessment and hepato-protective activity in Paracetamol-induced 
hepato-toxicity model in Wistar rats.  
2. Materials and Methods 
2.1. Materials 
TQ was purchased from M/s Sigma Aldrich, Mumbai, India. Phospholipon 90G (PL90G) was 
received ex gratis from M/s Phospholipid GmbH, Nattermannallee, Germany. Ethanol was 
purchased from M/s Merck Specialities Pvt. Ltd., Mumbai, India, while Span 80 and Tween 80 
from M/s Qualikem Fine Chemicals Pvt. Ltd. Vadodara, India, Glyceryl monostearate (GMS) and 
stearic acid were obtained from Hi-Media Pvt. Ltd., Mumbai, India, and Capmul was procured 
from, M/s Biochem Pharmaceutical Industries. Olive oil, castor oil and oleic acid were purchased 
from M/s Loba Chemie Pvt. Ltd., Mumbai, India. 
Wistar rats (250-300 g) used in the current study were procured from Animal house facility of 
National Institute of Pharmaceutical Education and Research, Mohali, Punjab, India and kept at 
the animal house establishment of Shoolini University, Solan, HP, India. Animal studies were 
conducted with prior approval of Institutional Animal Ethical Committee of Shoolini University 
(IAEC/SU/17/07). Rats were housed in plastic bottom cages and allowed free access to standard 
animal feed and water. The animals were maintained at a temperature of 25 ± 2 °C with relative 
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humidity of 45 ± 5%. The animals were initially acclimatized to experimental laboratory 
conditions for 7 days before the experiments. 
2.2. Screening of liquid lipids 
Selection of various liquid lipids viz. olive oil, capmul, oleic acid, and castor oil was done based 
on their solubility in TQ. Direct exposure of the drug to sunlight was avoided by working carefully 
in a dark hood within the laboratory. About 10 mL of oil was placed in 15 mL culture tubes and 
excess amount of TQ was added into it maintained at thermostatically controlled shaker water bath 
maintained at 37±1°C. Further, the weighed quantity of clear solution was dissolved in ethanol 
and analyzed spectrophotometrically after suitable dilution (s).  
2.3. Screening of solid lipids 
Solubility studies for TQ were carried out in various lipids, viz. Compritol, stearic acid and GMS. 
Excess amount of drug was added into 100 mg of solid lipid taken in a 5 mL culture tube 
maintained at thermostatically controlled shaker water bath at 70±1°C to get a clear solution. 
Further, the weighed quantity of clear solution was dissolved in ethanol and analyzed 
spectrophotometrically after suitable dilution (s). Whole study was carried in a dark hood within 
the laboratory to protect the drug from direct exposure to sunlight.  
2.2. Preparation of PNCs 
PNCs were constructed employing microemulsifcation technique with some modification. 
Initially, drug was dissolved in a portion of ethanol. The phospholipid was dispersed/dissolved in 
a portion of water along with Tween 80 to form the aqueous phase. Solid lipid was melted at 70°C 
and liquid lipid was completely mixed with it. Subsequently, lipid phase, aqueous phase and drug 
solution were mixed isothermally to obtain a clear microemulsion. The remaining portion of water 
was cooled at 4°C. The hot microemulsion so formed was poured into ice-cold water previously 
maintained at 4°C and stirred continuously for 20 min at 3000 rpm to get the PNCs [15, 25-28] . 
2.3. Systematic optimization and validation of PNCs  
TQ-loaded PNCs were optimized using three-level, Box–Behnken design (BBD). The selected 
dependent variables were the amount of solid lipid (X1), liquid lipid (X2), and Smix (X3), employed 
at three different levels of each variable, viz. low (-1), intermediate (0), and high (+1). Various 
PNC formulations (Table 1) prepared as per the design were investigated for the response variables 
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viz. particle size, and percent entrapment efficiency (%EE). Optimization data analysis was 
performed after evaluating prepared PNCs for the response variables. The response surface 
analysis was studied employing  three dimensional (3D) response surface plots, and two-
dimensional (2D) contour plots, generated using Design Expert® ver.10.0.1 (MS Stat-Ease Inc., 
Minnepolis, MN) [24,28]. 
Validation of methodology was done by selecting 17 PNCs formulation from the numerical 
optimisation technique based on desirability function. The validated formulations were evaluated, 
and the observed and predicted values were critically compared for the responses.
2.4. Particle size determination and zeta potential 
The particle size of the prepared PNC’s was determined by dynamic light scattering (Zetasizer 
2000 HS, Malvern Instruments Limited, Malvern, UK), installed at Chemistry Department, Panjab 
University, India. Whereas, zeta potential was measured by Delsa Nano C (Beckman Coulter 
LS13320), installed at University Institute of Pharmaceutical Sciences (UIPS) India. The 
formulations (0.1mL) were diluted up to 100mL with distilled water and mixed well before 
analysis at room temperature. The measurements were made at a detection angle of 90°, and the 
measurement position within the cuvette was automatically determined by the software.  
Approximately 1 mL of the sample was placed in the cuvette and the intensity of fluctuation of the 
laser beam was recorded, correlated with the particle size of the dispersed phase [29]. 
2.5. Percent Entrapment efficiency (%EE) 
The %EE of TQ-PNC was determined by measuring free TQ in the aqueous phase, which was 
separated using ultrafiltration centrifugation. Approximately 1mL of TQ-PNCs was centrifuged at 
3000 rpm for 20 min. and filtered using Filter Unit 100 kDa (Millipore Co., Boston, USA). The 
supernatant (0.1 mL) was dissolved in ethanol (1 mL), and analyzed using HPLC method. %EE of 









Wherein T is the total amount of drug detected in both the supernatant and sediment, and C is the 
amount of drug detected only in the supernatant
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2.6 Diffraction scanning calorimetry (DSC) 
The DSC pattern of pure TQ, freeze dried TQ-loaded PNC, sucrose, Capmul and stearic acid were 
recorded via.  NETZSCH leading Thermal Analysis (DSC 204, F1 Phoenix ASC) (Germany). The 
samples (drug, lipid and formulation) were scanned in an aluminium pan at heating rate of 10 
◦C/min over the temperature range of 20–350 ◦C under an inert argon atmosphere at a flow rate of 
20 mL/min. to evaluate the stability and compatibility 
2.7. Electron Microscopy 
Transmission electron microscopy was used to determine the morphology of optimized PNC with 
the help of transmission electron microscope (TEM) installed at Indian Institute of Technology 
(IIT), Mandi, H.P., India. The PNCs were negatively stained with 1% (w/w) aqueous solution of 
phosphotungstic acid, and dried on a microscopic carbon-coated grid, and viewed under the 
microscope at suitable magnifications. 
Field emission-scanning electron microscopy (FE-SEM) of the lyophilized sample was also 
performed to see the morphology of TQ-loaded PNCs. Samples were located on carbon conductive 
tap and placed inside the vacuum chamber [30]. Moving electron from tungsten filament was made 
the incident to the sample and surface morphology of nanoconstructs was determined by using FE-
SEM (Hitachi s-4800), installed at SAIF, Panjab University, Chandigarh, India.
2.8. X-ray diffraction (XRD) 
The XRD pattern of pure TQ, freeze dried TQ-loaded PNC, sucrose, Capmul and stearic acid were 
recorded via. X’Pert PRO diffractometer system (Panalytical, Netherlands) with a Copper Kα 
radiation (1.54060 A) [31]. The tube voltage and current were fixed at 45 kV and 40 mA 
respectively. Each samples was placed in an aluminum container and measured by a continuous 
scan between 5 and 40° in 2θ with a step size of 0.017 [2]. 
2.9. FTIR spectroscopy 
Infrared spectroscopy was performed by Attenuated total reflection Fourier transform infrared 
spectrometer (ATR-FTIR) to determine interaction between excipients, and the active drug i.e., 
TQ. 
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2.10. In vitro drug release kinetics 
In vitro drug release was performed via dialysis membrane method. The membrane was made into 
pouches by tying the thread on both the ends, and both pure TQ suspension and equivalent TQ-
loaded PNCs were placed into the bags separately. The dialysis bags were then placed in a beaker 
containing in 25 mL of release media kept in water bath shaker maintained at 37°C and run at 100 
strokes/min [32]. For first 2 h, release was carried out in 0.1N HCl (pH 1.2) followed by phosphate 
buffer (pH 6.8) up to 12 h along with 2.5% w/v of Tween 80. Aliquots of 2 mL were withdrawn 
at regular time intervals and replaced with an equal amount of diffusion medium to maintain the 
sink conditions. Samples were then analyzed using HPLC at λmax of 254 nm after appropriate 
dilution(s). 
To study the release mechanism of the drug from PNC, the in vitro release data was fitted into 
various mathematical models viz. zero order, first order, Higuchi model and Korsermeyer Peppas 
model [33]. The kinetic model was selected on the best fit with the highest value of regression 
coefficient (r2). 
2.11. In vitro drug release kinetics in simulated gastric fluid (SGF) and simulated intestinal fluid 
(SIF) 
In vitro drug release was performed via dialysis membrane method. The membrane was made into 
pouches by tying the thread on both the ends, and both pure TQ suspension and equivalent TQ-
loaded PNCs were placed into the bags separately. The dialysis bags were then placed in a beaker 
containing in 25 mL of release media kept in water bath shaker maintained at 37°C and run at 100 
strokes/min [32]. For first 2 h, release was carried out in  SGF (pH 1.2) followed by SIF (pH 6.8) 
up to 8 h along with 2.5% w/v of Tween 80. Aliquots of 1 mL were withdrawn at regular time 
intervals and replaced with an equal amount of fresh diffusion medium to maintain the sink 
conditions. Samples were then analyzed using HPLC at λmax of 254 nm after appropriate dilution(s) 
and the cumulative amount of drugs released was calculated. 
2.12. Stability studies 
The stability of the developed formulation was studied in simulated gastrointestinal (GI) fluids 
(SGF pH 1.2 and SIF pH 6.8). Briefly, 10ml of simulated GI fluids were added into 2 mL of PNC 
and incubated for 2 h in case of SGF (pH 1.2) and for 6 h in case of SIF (pH 6.8). Following the 
incubation, the formulation was evaluated for particle size, PDI and %EE. 
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2.13. Caco-2 cell culture studies 
2.13.1. Qualitative Uptake study 
For the qualitative cell uptake study the Caco-2 cells were employed at a density of 50,000 
cells/well in 6 well plate (Costars, corning Inc., NY, USA). The harvested cells were seeded and 
kept overnight for the attachment of cells. Afterward, the incubation of the cells was done with 
free Coumarin 6 (C-6) and C-6 loaded PNC (equivalent to 1 μg/mL of free C-6) for 3 h. The 
medium was removed after the incubation was finished. Further, Hank’s balanced salt solution 
(HBSS) was used for washing the cells thrice followed by observing under the Confocal Laser 
Scanning Microscope (CLSM) (Olympus FV 1000) [34].  
2.13.2 Quantitative uptake 
The quantitative cell uptake study was performed as per the previous report [34]. Briefly, Caco-2 
cells were seeded at a density of 1x105 cells/well in six well cell culture plates (Costars, Corning 
Inc., NY USA). The medium of cell culture was replaced with fresh medium having a set 
concentration (10 μg/mL) of native TQ and PNC and further incubated for variable time intervals 
of 0.5 h to 3 h to evaluate the time dependent cell uptake. After, the period of incubation was 
accomplished the pre-existing medium was discarded followed by washing of cells thrice by 
HBSS. Further, the lysis of the cells was done with 0.1% Triton™ X-100 and methanol was 
employed for extraction in order to solubilize the drug, which was internalized. Finally, the 
centrifugation (Sigma K 300, USA) of cell lysates, which were obtained, was done at 34,000 rcf 
for a period of 10 min. The supernatant obtained was then quantified for TQ with the aid of 
validated HPLC method. 
2.14. In vivo studies 
2.14.1. Oral pharmacokinetics 
The rats were randomly divided into two groups (n = 6). The first group was orally administered 
with TQ (20 mg/kg) dispersed in 4% sodium carboxymethylcellulose (CMC-Na) and for second 
group single dose of TQ-loaded PNCs (20 mg/kg) was administered. Blood samples of about 0.5 
mL each were withdrawn from the retro-orbital plexus under light anaesthesia at specified time 
intervals (pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 18, and 24 h), placed into heparinized eppendorff 
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tubes and instantly centrifuged at 3000 rpm for 15 min. [2, 26]. After centrifugation, the plasma 
obtained was stored at −40 °C until further analysis. Extraction of TQ from rat plasma was 
performed and analyzed employing HPLC. The plasma obtained was stored at −40 °C until further 
analysis. An aliquot of 200 μL of plasma-containing drug (TQ) was then placed in centrifuge tube 
and precipitated with equal volume of acetonitrile (200 μL). Further, methanol was added to make 
up the volume up to 1 mL. The mixture was then centrifuged at 6000 rpm for about 10 mins. 
Supernatant (20 μL) was injected onto the column for the analysis of TQ employing HPLC [35]. 
The pharmacokinetic analysis was performed by fitting the obtained data into one compartment 
open body model (1CBM) extravascular model and various pharmacokinetic parameters Cmax, 
t1/2, tmax, Vd, AUC(0-24), AUC(0-∞) and F were calculated using Microsoft Excel add-in, 
“PKSolver”. 
2.15. PCM-induced hepato-toxicity 
The rats were randomly divided into 5 groups (n = 4) namely normal control group (Group I), 
which were provided a daily dose of 1 mL aqueous solution of 0.9 % w/v sodium chloride (NaCl) 
(p.o.) for 7 days. Toxic group (Group II) received (650 mg/kg) PCM once daily for 7 days to 
induce hepatic damage. TQ-suspension (Group III) dispersed in 4% sodium 
carboxymethylcellulose (CMC-Na) (1mL) (20mg/kg) were administered orally, TQ-loaded PNC 
suspension group (Group IV) received (20mg/kg) daily dose for 7 days, and standard group treated 
with an oral suspension of Silymarin tablet (SILYBON®) (40 mg/kg) for 7 days (Group V) 
(40mg/kg). The rats in the toxic group (Group II) was given oral dose of 650 mg/kg (PCM) for 
seven days. All the groups, including toxic group (group II), except group I (control) received 
concurrent dose of 650 mg/kg PCM p.o for 7 days, while the rats in the normal control group was 
given the vehicle (normal saline) only. After 7 days, about 1 mL of the blood sample was 
withdrawn from the retro orbital plexus under light ether anaesthesia. The blood was collected in 
non-heparinized tubes, centrifuged at 1500 rpm for 15 min, the serum was separated and frozen at 
−80◦C until further testing. The serum so obtained was analyzed for various enzymes such as 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphate (ALP), 
bilirubin and albumin respectively [12,36-37]. 
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2.16. Histopathological examination 
Liver tissue samples were excised on the last day of the study. The samples were washed with 
phosphate buffer saline, dried with tissue paper and preserved in 10% formalin solution. These 
liver sections were stained with haematoxylin and eosin (H&E) and examined under a light 
microscope for the presence of any necrosis, haemorrhage, and inflammatory cells. 
Statistical analysis 
The data obtained are reported as mean ±SD. Data statistical analysis was performed by Graph 
Pad Prism 8.0. The data from different formulations were compared for statistical significance by 
the one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison Test. A 
difference was considered statistically significant at the level of p < 0.05.  
3. Results  
3.1. Formulation and optimization PNC formulation 
The maximum solubility of TQ was obtained in the stearic acid (solid lipid) and capmul (liquid 
lipid) (data not shown), thus selected for the development of PNCs. For the optimization of TQ-
loaded PNCs, a three-factor, three-level Box-Behnken design was employed [24]. Table 1 
summarises an account of the 17 experimental runs studied, along with the coded values and actual 
values for the studied factors. The %EE, and particle size values obtained for the various PNC 
formulations are enumerated in table 1 and figure 1 (a-f) 
The data analysis was carried out by analysing the response variables employing second-order 
quadratic polynomial models (p<0.0001) [28]. The r2 values for these models (particle size = 
0.9903; %EE = 0.9909) indicating excellent goodness of fit. The models was also found to have 
insignificant values of ‘‘lack of fit’’ endorsing the relevance of proposed model was appropriate. 
Closeness in the magnitude of adjusted and predicted r2 to the actual model r2 also supported an 
excellent good of fit to the data. 
3.1.1 Model Generation 
The data analysis was carried out by analysing the response variables employing second-order 
quadratic polynomial models (p<0.0001) [26]. Application of ANOVA suggested that the chosen 
quadratic model was highly significant (p<0.05) along with the model terms (p<0.0001). The r2
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values for these models (particle size = 0.9903; %EE = 0.9909) indicating excellent goodness of 
fit. The models was also found to have insignificant values of ‘‘lack of fit’’ endorsing the relevance 
of proposed model was appropriate. Closeness in the magnitude of adjusted and predicted r2 to the 
actual model r2 also supported an excellent good of fit to the data. The special polynomial 
mathematical model encompassing ten coefficients (β0- β33) was postulated with β0 as the 
intercept. All the coefficients represent quadratic and interaction terms, as depicted in Eq. 2 
Y=β0 + β1X1 + β2X2 + β3X3 + β12X1X2 + β13X1X3 + β23X2X3 + β11X12 + β22X22 + β33X32        (2) 
  3.1.1.2 Model Optimization 
Optimization was done based on desirability function in order to get the desired goal for the 
response variables. The optimum formulation was selected based on the criteria, i.e., minimum 
value of particle size and maximum value of %EE by applying constraints. The desirability 
function, ‘r’ near or equal to unity was assigned as an indicator of the best-fit composition with 
desired features. Table 2 presents various constraints and possible solutions with their numeric 
range of desirability.
3.1.1.3 Model Validation 
A total of 7 check-point formulations were chosen from the RSM, evaluated and the observed data 
compared with the predicted responses (Table 3). Linear correlation plots drawn between the 
actual and the predicted response variables demonstrated high values of r2. (particle size = 0.9879; 
%EE = 0.9552) indicating excellent goodness of fit. The overall bias for response variables found 
to be -0.044 ± 0.096%, indicating very high degree of predictive ability of the QbD experiments. 
The residual plots were found to be quite regulated, as they showed uniform, relatively narrow and 
random scatter around the zero-axis.  
3.2. Characterization of optimized PNCs 
Particle size of the optimized PNC was less than 100nm (i.e. 83.5nm and %EE of the optimized 
PNC was found to be 94.4%. The particle size distribution (PDI) was found to be 0.55, which is 
in acceptable range [38], as shown in Figure 2(a). The zeta potential value was obtained to be 
−0.64.  
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DSC analysis revealed the melting point of TQ, stearic acid, capmul and PNC. DSC thermogram 
of TQ showed sharp endothermic peak around 47 °C, which corresponds to its melting point range, 
as mentioned in the literature (45-50 ◦C). Whereas, stearic acid, capmul and PNC exhibits a sharp 
endothermal peak at 60 °C, 150 °C and 165 °C respectively as shown in figure 2 (b).  Whereas 
(figure 2(c) and (d) shows the TEM and FE-SEM photomicrographs of the developed nanocarrier 
system, respectively. The TEM images of optimized PNCs reveal that the particles were spherical 
in shape, in agreement with the size obtained using DLS i.e. below 100 nm. The SEM images also 
displayed nearly spherical topography of prepared PNC’s. No crystalline drug particles were 
visible as shown in Figure 2(c,d). The XRD pattern of pure TQ, TQ-PNC, sucrose, Capmul and 
stearic acid is displayed in Figure 2(e). The XRD pattern of the pure TQ demonstrates high 
intensely peak, showing its crystalline nature, while stearic acid and Capmul exhibited 
comparatively low intensity peaks indicating their amorphous nature. TQ-PNCs demonstrated a 
marked decrease in the intensity of TQ peak.  
For the estimation of any possible chemical interaction among TQ and excipient, FTIR spectra of 
TQ, Physical mixture, sucrose and stearic acid, Overlay spectra, of drug, the excipients, and 
physical mixture is represented in Figure 2(f), while their interpretations, are included in the Table 
4. The FTIR spectrum of the pure TQ showed the sharp peak at 2970 cm−1  corresponds to (free 
CH stretching, 2800-3200 cm−1), the peak present at 1644 cm−1 corresponds to (C=O and C=C 
stretch,1670-1820 cm−1), the peak present at 1360 corresponds to  (-CH bending, 1350-1480 cm−1). 
The FTIR spectrum of stearic acid exhibited peaks at 3492 cm−1 corresponds to (-OH stretch, 3200-
3600 cm−1), the peak presented at 2920 cm−1 corresponds to (-CH stretch, 2850-3000 and  peak at 
1707 corresponds to (C=O stretch and C=C stretch, 1670-1820 cm−1).  The FTIR spectrum of 
sucrose exhibited a sharp peak at 2927 cm−1 corresponds to (-CH stretch, 2850-3000 cm−1). The 
peak presented at 3667 cm−1 corresponds to (-OH stretch, 3500-3700) peak appeared at 1395 cm−1
corresponds to (-CH stretch, 1350-1480).  There was a shifting of the peak of TQ benzene ring and 
carbonyl, group (C=C, C=O) from 1644cm −1 to and 1771 cm−1 in the physical mixture. 
3.3. In vitro release kinetic 
The release profile of TQ from plain TQ suspension and optimized PNC formulation is shown in 
Figure 2(g). It is vivid from the results, that there was much better release of the drug from PNCs 
vis-à-vis plain TQ suspension. Approximately 80% of the drug was released from TQ-PNCs up to 
12h, whereas, only 50% of TQ was released from pure TQ suspension. In initial 2 h, approximately 
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31.5% of the drug was released from PNC vis-à-vis pure TQ (10.8%) followed by sustained release 
at a constant rate.  
After fitting the release data into various kinetic models, the best-fit model was found to be Higuchi 
model, which indicated the controlled release behavior of the drug from PNC matrix. 
3.5. In vitro drug release (SGF) and (SIF) 
The release profile of TQ from plain TQ suspension and optimized PNC formulation is shown in 
Figure 2(h). Almost 100% of the pure TQ drug release was achieved within 1 h, which indicated 
the rapid diffusion of TQ. In case of PNCs initial burst release was seen in the first 30 mins which 
was nearly 40% of the total amount of TQ released, followed by a sustained release of the 
remaining TQ over nearly 8 h (91.74%) [Figure 2(h)].  
3.6 Stability of PNC in simulated GI fluids 
As PNC was designed for oral administration, therefore the main goal behind stability study in 
simulated GI fluid is to first protect the drug from degradation while passing through harsh 
environment in GI tract. PNC were able to maintain their integrity upon incubation with simulated 
GI fluids for specified time. The results showed the insignificant changes in all the formulation 
parameters viz. particle size, PDI and %EE (Table 5).  
3.7 Qualitative and quantitative cell uptake 
The uptake of PNC were assessed in Caco-2 cells to predict the possibility of GI membrane 
associated transport. CLSM images of PNC exhibited higher fluorescence vis-à-vis pure TQ. 
Figure. 2(i) (I) and (II) depicts CLSM images of pure TQ and respectively. Similarly, quantitative 
uptake of PNC and pure TQ in Caco-2 cells was performed to further validate the outcomes of 
CLSM analysis. The time dependent cell uptake of pure TQ and PNC by Caco-2 cells is depicted 
in Fig. 2(j). The study showed significantly higher uptake (p < 0.05) of PNC vis-a-vis pure TQ. In 
addition, the cellular uptake was improved when there was an increase in the incubation time from 
0.5 to 3h. After 3 h of interval, the % cell uptake was 7.2 % and 41.2 % for pure TQ and PNC 
respectively at concentration 10 μg/mL. 
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3.6. Oral pharmacokinetics  
The plasma concentration-time profile graph of optimized PNC formulation exhibited better 
enhancement in in vivo absorption of TQ vis-à-vis TQ suspension as shown in figure 3 (A). Various 
pharmacokinetic parameter for TQ-PNC and TQ suspension is entailed in Table 6. The tmax value 
was detected to be 3.96 h for TQ-PNC and 3.0 h for pure TQ suspension. Whereas, t1/2 was found 
to be 2.60 h for TQ-PNC and 2.13 h for pure TQ suspension. Volume of distribution (Vd) was 
found to 0.077 L/kg for PNC and 0.251 L/kg for TQ, clearance (CL) was found to be 0.020 L/kg/h 
for PNC and 0.081 L/kg/h for TQ. Cmax value was found to be 97.06 μg/mL for TQ-PNC and 29.83 
μg/mL for pure TQ suspension. While, AUC(0-t) and AUC(0-∞) of TQ-PNC were found to be 
965.614 and 976.29 μg.h/mL, respectively, which were highly significant (P<0.05) in comparison 
with AUC(0-t) (243.53 μg.h/mL) and AUC(0-∞) (244.29 μg.h/mL) of pure TQ suspension. TQ-PNC 
showed relative bioavailability of 399.64% based on mean AUC(0–∞) compared to TQ-suspension, 
indicating the improved bioavailability of the drug in the phospholipidic nanoconstructs.  
3.5. Hepatoprotective activity 
3.5.1. Serum biochemical estimation 
In vivo hepato-protective effect of TQ-PNCs was studied against PCM-induced hepatotoxicity. 
PCM administration produced a significant hepatotoxicity. Result of biochemical parameters 
(ALT, AST, ALP, albumin and total bilirubin) for various groups are given in Table 7 and Figure 
3 (B). Severe liver damage in the toxic group can be seen by significant increase in the marker 
enzymes. Compared to the control group and treatment groups (pure TQ, PNC and silymarin 
group), PCM administration induced significant increase in ALP, ALT, AST, bilirubin and 
albumin level production (p <0.001). Treatment for seven days caused the reduction in the ALP, 
ALT, AST, bilirubin and albumin levels in all the treated groups. Plain TQ suspension revealed 
almost same levels of biomarker enzymes vis-a-vis standard treatment however, encapsulation of 
TQ in the PNC significantly reduced the liver biomarker enzymes. 
3.6. Histopathological evaluation  
The results of histopathology of normal, toxic control, TQ suspension, optimized PNC and 
Silymarin group are presented in Figure 3 (C). Normal group animals showed normal liver with 
no signs of inflammatory cells and necrosis and showed the usual lobular building. While the 
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sections of toxic group showed notable changes viz. parenchymal cell injury, lymphocytes and 
macrophages infiltration including necrosis and degeneration. However, the animals treated with 
TQ suspension presented no sign of inflammation and necrosis with minor lymphocytic 
infiltration. While TQ-PNC treated, animals showed normal lobular architecture in a more distinct 
manner as compared to TQ suspension, and similar to normal group with few lymphocytes and 
normal vacuoles. The standard treatment group, i.e., Silymarin, showed almost normal appearance 
of liver parenchyma, however with few scattered foci with no signs of inflammation and necrosis 
in hepatocytes. 
4. Discussion
In the recent past, there has been a tremendous resurgence of research on the bioactive components 
isolated from the plants, for their prophylactic and therapeutic worth. The strong antioxidant and 
anti-inflammatory effects, has made TQ a convincing candidate for the treatment of 
hepatoprotective disorders, as evidenced from the previous literature. However, like other plant- 
based molecules the delivery of TQ via oral route is difficult, owing to its poor biopharmaceutical 
properties. The aim of this paper was to encapsulate TQ inside the phospholipidic nanoconstructs, 
which can protect the drug, enhance the bioavailability, and target the drug to the liver and thereby, 
releasing the drug in a controlled manner. For the development of PNCs, determination of 
solubility of the drug in solid lipids, and liquid lipid is a critical aspect. The solubility of the drug 
in lipids is the most significant, as the ability of the PNCs to maintain the drug in solubilized form 
is largely influenced by the solubility of drug in the lipidic core of the nanoconstructs. To construct 
the PNCs, phospholipid was employed as the surfactant. However, it is reported that phospholipids 
are able to increase the crystallization temperature (Tc) of triglycerides by acting as a template for 
surface heterogenous nucleation. Phospholipid molecules bound to vesicles, exhibit only a limited 
mobility and thus, fail to immediately cover the newly created interfaces during recrystallization. 
Due to the low mobility of the phospholipid molecules, sudden lack of emulsifier on the surface 
of the particle leads to particle aggregation and increase in the particle size of lipidic 
nanoconstructs [39]. Thus, the blend of nonionic surfactants are required to regulate and balance 
the crystallization, which can further stabilize the particle size of nanoconstructs [40].
TQ-loaded PNC formulations were optimized employing BBD to get the best optimal composition, 
and investigated for %EE, and particle size as the response variables. In the current studies, all the 
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input variables, i.e., the amount of solid lipid, liquid lipid and Smix had a significant impact on the 
particle size. A nonlinear dip in the values of particle size followed by a rising trend was observed 
with increase in the liquid lipid and solid lipid concentration (Figure 1a). Similarly, a twisted 
shaped graph is obtained in the case of Smix and solid lipid, as there was a non–linear increase in 
particle size with increase in Smix. Firstly, there was a decreasing trend in particle size up to the 
mid-level of Smix, followed by a slight increase in the particle size. Whereas, in the case of solid 
lipid there was a sharp initial decline in the particle size followed by a rising trend (Figure 1b). 
Furthermore, (Figure 1c) depicted that with increase in Smix and liquid lipid concentration, the 
particle size tended to decrease first, followed by a non-linear increase in both the cases. With the 
increase in lipid concentration, an increase in particle size can be due to decrease in emulsifying 
efficiency of surfactant and thus, increase in particle agglomeration. Figure 1(d-f) depicts the 2D-
contour plots and 3D-response surface plots for %EE. However, all the input variables had a 
positive influence on the % EE of the drug, yet Smix had a more pronounced effect. Both liquid 
lipid and solid lipid at all the levels positively influenced the %EE of the drug. With increase in 
the liquid lipids concentration, there was an upsurge in the %EE of drug up to a certain level and 
then it became constant. While in the case of solid lipid a non-linear increase in the %EE was 
observed (figure 1d). However, it can be seen from the figure 1(e, f) that with increase in the Smix, 
there was sharp rise in the %EE of the drug vis-à-vis solid lipid and liquid lipid. This is attributed 
to the fact that high lipid and Smix concentration allows the better stabilization and solubilization 
of drug in the lipid blend, thus led to the enhancement of %EE.  
Optimized TQ-PNC formulation showed smallest particle size (83.5nm) which was possibly due 
to the presence of optimal combination of PL90G and T80 (1:1) as Smix at appropriate 
concentrations. The presence of nonionic surfactants and their blends with phospholipids often led 
to the particle stabilization. 
PDI is a parameter, which is used to define the size distribution of the lipidic nanoconstructs. The 
PDI value (0.55) was in the acceptable range of uniformity. The acceptable value for PDI ranges 
between 0.05 to 0.7, whereas the values greater than 0.7 indicate that the sample has a very broad 
size distribution [41,42].The zeta potential value was close to zero (−0.64), which is due to the 
presence of a non-ionic surfactant T80, responsible to stabilize systems by creating spatial 
inclusion [43,44]. The %EE of the optimized PNC was found to be 94% revealing that the 
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microemulsification method with the apt optimization of solid lipid, liquid lipid and Smix
(T80:PL90G) can yield such high value of %EE. Further, it has been observed that high 
phospholipid content reduces the risk of drug loss to the external phase, and thus provide more 
space to incorporate the drug, resulting in improved entrapment efficiency. This may also be due 
to an excess of phospholipid possibly forming multilayers around the particle. 
The DSC thermogram of PNC does not show any peak pertaining to thymoquinone, which reveals 
the complete entrapment of TQ in the lipidic nanocarriers. The presence of both solid and liquid 
lipid mixture can lead to less ordered lipid crystalline arrangement. The shifting of TQ melting 
peak in the curves can be associated to the amorphous structure of PNC and complete 
solubilization of drug within the PNC [45]. The surface morphology of optimized PNCs reveal 
that the particles were spherical in shape, in agreement with the size i.e. below 100 nm. SEM 
observation showed a dense solid spherical topography having smooth surface of the PNC. 
Moreover, no crystalline drug particles were visible. The XRD pattern of the pure TQ demonstrates 
high intensely peak, showing its crystalline nature compared to TQ-PNCs. A marked decrease in 
the intensity of TQ peak in TQ-PNC, indicating the solubility and stability of the drug in the PNC 
core. In FT-IR study, all the peaks relating to functional groups (hydroxyl, methyl, carbonyl) of 
all the excipients are intense and clear in the FTIR spectrum of the physical mixture. Thus, it can 
be inferred that there was no interaction between the drugs and the excipients, employed in various 
nanocarrier formulations. Also, the drug was stable and compatible with the excipients. 
TQ-PNC showed significantly high drug release compared to pure TQ.  It was observed that 
approximately 30% of the drug was released from PNC in first 2 hours vis-à-vis TQ followed by 
sustained release at a constant rate. This might be due to the presence of lipidic core and can be 
explained in three aspects, i.e., the presence of drug at the surface of PNCs, secondly liquid lipid 
and thirdly, smaller particle size [46]. In first case, TQ might be adsorbed at the surface of the 
nanoconstructs due to the presence of Smix, secondly liquid lipid was distributed in solid lipid core, 
which leads to the formation of imperfect crystalline structure of PNC and thus increasing the rate 
of drug release [47]. In third case, smaller particle size in case of optimized PNC formulation offers 
the greater surface area, and hence, improves the contact between particles and dissolution 
medium. The best-fit model for PNCs was found to be Higuchi model indicating the controlled 
release mechanism of drug release from the nanoconstructs. This could be ascribed to the lipophilic 
19 
nature of TQ, which is entrapped deeply in the lipidic core matrix in the solubilized form and 
thereby, slow diffusion of drug molecules via the phospholipid matrix of PNCs. The release profile 
of TQ from plain TQ suspension and optimized PNC formulation from GI fluids is shown in Figure 
2(h). The initial burst of TQ release from the PNC may be due to the presence of TQ molecules on 
the surface closest to PNC particle. The sustained release phase may be associated to the diffusion 
of TQ molecules from the lipid core, which leads to the immobilization of drug from the PNC 
molecule. In addition, it may be because of the effect of decreasing TQ amount [48]. 
A stability test in simulated GI tract was designed to investigate the effect of composition on 
stability of nanocarriers. As said earlier the main aim behind stability study in simulated GI fluids 
was to first protect the drug from degradation from the harsh GI tract environment until it reaches 
the intestine. After reaching in the intestine, drug will be digested by intestinal enzyme to form 
mixed micelles composed of lipid degradation products (fatty acids, monoglycerides etc.), bile 
salts and phospholipids entrapping drug thus enhancing its bioavailability. The results showed the 
insignificant changes in all the formulation parameters viz. particle size, PDI and %EE (Table 5). 
Although, PNC was found to be more stable in SIF compared to SGF. This stability of PNC in 
acidic pH might be due to presence of nonionic surfactants i.e., T80, which leads to the steric 
stabilization effect. These nonionic surfactants are unresponsive to flocculation and coalescence 
in low pH due to their molecular structure. Whereas in case of SIF particle aggregation can occur 
sometimes due to the  release of surfactant layer from the surface of lipidic nanocarriers by lipase, 
thus leading to nanocarrier aggregation and exposing the surface of nanocarriers for lipid 
hydrolysis by intestinal enzymes [49]. 
The cellular uptake of PNC were assessed in Caco-2 cells [(Figure 2(i) (I-II) and 2(j)]. The particle 
size of PNC was found to play important role in the efficient uptake through GIT. The size of PNC 
was found to be less than 100 nm. This confirmed the effective intestinal uptake, mostly in the 
lymphoid region, which helped in bypassing the first pass metabolism. In addition, the large 
surface area by nanosized PNC enhances the contact between the drug and the cell membrane, 
thereby augmenting the cell uptake of drug. Furthermore, the combined mechanism between lipids 
and surfactants can improve drug absorption by enhancing affinity for cell membranes with 
lipophilicity. Therefore, these results supported that TQ could be taken up into Caco-2 cells by 
amalgamation into PNC [50]. 
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In in vivo animal pharmacokinetics, TQ-PNC showed 3.9-fold enhancement in the relative 
bioavailability vis-à-vis TQ-suspension, indicating the improved bioavailability of the drug in the 
lipid-based nanoparticles formulation. The improved pharmacokinetic and oral bioavailability of 
the TQ from lipidic matrix was probably because of combined promotion mechanisms. Firstly, the 
ability to adhere to gut wall. The ultrafine dispersions within nanometer range imparts them with 
a tremendous specific surface area and thus the possession of adhesion to gut wall, which is helpful 
to oral absorption. Secondly, the nano-sized formulation and the presence of Smix as suitable 
solubilizers of TQ in lipidic core. Furthermore, faster absorption of TQ incorporated into lipidic 
matrix helped in avoiding first pass extensive gut wall metabolism due to close association of drug 
with lipid vis-a-vis plain TQ. Thirdly being a lipid-based system, PNCs may promote the uptake 
by M-cells in the Payer’s patches and increase the absorption through the lymphatic pathway [51].  
The observations from biochemical parameters showed that compared to the control group and all 
the groups including TQ-PNC showed significant decrease in ALP, ALT, AST, bilirubin and 
albumin level production (p <0.001) after PCM administration. Whereas reduction in the 
biomarker enzyme was more pronounced in the TQ-PNC group compared to all other groups (p 
<0.001). The effect may be assigned to the higher cellular permeability of TQ achieved by PNCs. 
PNCs with the blend of T80 and PL90G as a surfactant and co-surfactant, respectively, are 
anticipated to interact with the membrane lipids of liver cells resulting in physiologically 
significant effects as shown in this study [52]. Moreover, other hypothesis can be ascribed that the 
passage across endothelial fenestrations of carriers smaller than 100 nm can effectively target 
hepatic stellate cells HSCs (in rats). In addition, the presence of lipidic carrier facilitates capture 
by the liver and other organs. Overall, these results specified that optimized TQ-PNC showed 
enhanced hepatoprotective effects against PCM-induced liver damage. The results of biochemical 
examinations were further supported by the histopathological investigations in rats liver samples. 
5. Conclusion  
The present research work, have successfully prepared TQ-loaded PNCs and systemically 
optimized employing BBD, which helped in providing the optimal composition of three 
independent variables to select the best-optimized formulation. The prepared nanoconstructs 
demonstrated initial burst release followed by controlled release. Pharmacokinetic studies proved 
the potential of nanolipidic carriers to alleviate the challenge of lower bioavailability of TQ. 
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Pharmacological effects of selected optimized PNC formulations showed significant reduction of 
various liver biomarkers compared to toxic group, which was further substantiated by 
histopathological examination of liver sections. Hence, we expect that these investigations can 
provide a new strategy for the development of nano-medicine and suggest TQ as a strong candidate 
for a new generation of hepato-protective molecule with reduced side effects in the not so distant 
future. The outcomes of the studies can be extrapolated to variety of bioactives and drugs with 
similar challenges and hurdles.   
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Figure 1. Two-dimensional contour plots and corresponding three-dimensional response surface 
plot depicting the effect of various input variables on; (a) Particle size; Liquid lipid(X2), solid lipid 
(X1); (b) Smix (X3), solid lipid (X1); (c) Smix (X3), Liquid lipid (X2) and effect of various input 
variables on %EE (d) Liquid lipid(X2), solid lipid (X1); (e) Smix (X3), solid lipid (X1); (f) Smix (X3), 
Liquid lipid (X2). 
Figure 2. (a) Particle size distribution of optimized PNC formulation, (b) DSC graphs of drug, 
PNC, capmul and stearic acid, (c) TEM microphotograph (at 60,000X) of TQ-loaded PNCs (d)
FE-SEM microphotograph (at 30,000X) of TQ-loaded PNCs, (e) XRD spectra of pure drug, PNC, 
sucrose, capmul and stearic acid .(f) Overlay FTIR spectrum of drug and the excipients A: TQ, B: 
Physical mixture, C: Sucrose, D: Stearic acid, (g) Comparative in vitro release of optimized TQ-
PNC and pure TQ, (h) Comparative in vitro release of optimized TQ-PNC and pure TQ in SGF 
and SIF, (i) Qualitative cell uptake of C-6 loaded PNC (I) Free C-6 and (II) C-6 loaded PNC, 
where (a) images under green fluorescence channel of C-6 pannel (b) corresponding differential 
interface contrast image of the cell (c) superimposition of the panel (a and b), Panel (d) and (e) in 
all the images shows vertical and horizontal line series of fluorescence along with the yellow line 
of the image (c) respectively. (j) The time dependent cell uptake of pure TQ and PNC by Caco-2
cells
Figure 3(A). Plasma concentration-time profile curve of TQ after oral administration of optimized 
PNC and TQ suspension (mean±SD, n=6) (B) Effect of various formulations on serum and tissue 
biochemical parameters. Data is presented as Mean ± SD (n = 4) and analyses by one-way analysis 
of variance followed by Tukey's Multiple Comparison Test. aP < 0.001 vs saline control, bP < 
0.001 vs toxic group and cP < 0.05 vs standard. (C) a) Normal control showed normal sinusoidal 
architecture and no fibrosis; b) Toxic  group showed Parenchymal cell injury with lymphocytes 
and macrophages infiltration, along with inflammation and apoptosis; c) TQ suspension group 
showed mild lymphocytic portal infiltrate; d) TQ-PNC showed few lymphocytes and normal 
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Figure 2 (a-j) 


















































                                                    e)
Figure 3 (B) 



















Experimental runs of BBD design matrix and their responses 
Table 2  
Constraints for numeric optimization and predicted solutions 
Table 3  
Comparison of experimental results with predicted responses
Table 4 
Drug-excipient interaction employing FT-IR 
Table 5 
Stability of PNC in simulated GI fluids 
Table 6 
Pharmacokinetic parameters (mean±SD) after oral administration of TQ –PNC and TQ suspension 
in rats (n=6) 
Table 7 
Effects of optimized TQ-PNC and TQ treatments on Serum and Tissue Biochemical Parameters 
(mean±SD, n=4)  
2 
Table 1 
Runs Solid Lipid Liquid lipid *Smix 
(T80:PL90G) 
%EE Particle size (nm)
1 0 0 0 99.2 88.9 
2 1 1 0 97.5 89.3 
3 0 1 1 83.78 91.5 
4 -1 0 1 98.4 89.6 
5 0 0 0 99.2 87.3 
6 1 -1 0 112.8 75.5 
7 0 1 -1 110.2 69.9 
8 0 0 0 100.6 85.5 
9 1 0 -1 109.2 72.5 
10 0 -1 1 106.1 78.3 
11 -1 0 -1 109.6 63.5 
12 0 -1 -1 109.3 63.3 
13 -1 -1 0 113.6 75.3 
14 1 0 1 90.5 87.3 
15 0 0 0 99.9 86.9 
16 0 0 0 96.5 85.5 
17 -1 1 0 105.3 84.9 
Independent variables (g) Level used, actual (coded) 
Low(-1) Medium (0) High(+1) 
Solid Lipid -1 0 +1 
Liquid Lipid -1 0 +1 
Smix -1 0 +1 
*T80:PL90G was fixed in the ratio of 1:1
3 




Upper limit Importance 
A:Solid lipid maximize -1 1 *** 
B:Liquid lipid is in range -1 1 *** 
C:Smix maximize -1 1 *** 
Particle size minimize 83.78 113.6 *** 
%EE is in range 63.3 91.5 *** 




1 0.69 1 83.44 90.17 1.000 Selected
1 0.85 1 82.37 90.48 1.000 
1 0.83 1 82.52 90.45 1.000 
1 0.938 1 81.93 90.55 1.000 
1 0.668 1 83.61 90.11 1.000 
1 0.993 1 81.66 90.57 1.000 













Particle size (nm) 83.44 83.47 -0.04 
%EE 90.18 90.12 0.07 
VAL-1 
Particle size (nm) 82.37 82.39 -0.02 
%EE 90.48 90.39 0.10 
VAL-2 
Particle size (nm) 82.52 82.42 0.10 
%EE 90.45 90.51 -0.07 
VAL-3 
Particle size (nm) 82.06 82.12 -0.10 
%EE 91.00 90.90 0.11 
VAL-4 
Particle size (nm) 82.76 82.70 0.06 
%EE 91.00 90.81 0.21 
VAL-5 
Particle size (nm) 81.93 82.00 -0.07 
%EE 90.54 90.50 0.04 
VAL-6 
Particle size (nm) 83.61 83.5 0.11 
%EE 90.19 90.10 0.10 
Table 4 
Reported Peaks (cm-1) Observed Peaks (cm-1) Assignment
TQ
1670-1820 1644, 1614 -C=O stretch 
2850-3000 2970,2925,2877              -CH stretch 
1350-1480 1360 -CH bending 
Physical Mixture
2850-3000 2929, 2853 -CH stretch
1670-1820 1741 C=O stretch
1900-2000 1920,1950 C=C stretch
3200-3600 3327,3387 -OH stretch
1350-1480 1350,1376 -CH stretch 
Sucrose
2850-3000 2987 -CH stretch 
3500-3700 3665 -OH stretch
1350-1480 1395 -CH stretch 
Stearic acid
3200-3600 3493 -OH stretch
2850-3000 2920 -CH stretch 
1670-1820 1707 -C=O stretch 
5 
Table 5 
Fluids Particle size (nm) PDI %EE 
Initial Final Initial Final Initial Final 
SGF 








89.4.5 0.59 93.5 
Table 6 
Parameters TQ suspension TQ-PNC
Cmax (µg/mL) 29.83 97.06 
t1/2 (h) 2.13 2.61 
tmax (h) 3.01 3.96 
Vd (L/kg) 0.25 0.07 
CL (L//kg/h) 0.08 0.02 
Ke 0.32 0.26 
AUC(0-24) (µg.h/mL) 243.53 965.14
AUC(0-inf) (µg.h/mL) 244.29 976.29
Relative bioavailability (F) 
(Ratio of AUC(0-t) of TQ-PNC 




Groups ALT (U/L) ALP (U/L) AST (U/L) Bilirubin 
(mg/dl) 
Albumin
Saline control 35.9±10.46 104.41±2.54 59.2±3.21 0.40±0.01 5.1±0.06 
Toxic control (PCM) 87.0±6.49 386.1±5.54 102.73±5.65 2.39±0.01 3.2±0.08 
TQ suspension 47.41±7.64 168.20±2.01 79.86±4.65 0.60±0.02 4.8±0.21 
TQ-PNC 39.2±9.23  110±1.67 69.7±2.55 0.58±0.03 4.5±0.04 
Silymarin 45.3±6.01 121.31±1.62 73.90±3.54 0.50±0.01 4.3±0.10 
Values were the means of three replicate samples. The data were presented as mean ± SD (n=4), ap<0.001 vs saline control, 
bp<0.001 vs toxic control and cp<0.05 vs Silymarin 
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